Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching (2022)

Peer-Reviewed Study · Kerr L, Cadegiani FA, Baldi F, Lobo RB, Assagra WLO, Proença FC, Kory P, Hibberd JA, Chamie-Quintero JJ · January 15, 2022

Kerr L et al., 2022-01-15: The Itajaí, Brazil citywide programme report: among 159,561 residents analysed, regular ivermectin users had 44% lower infection, 56% lower hospitalisation and 68% lower COVID-19 mortality than non-users after propensity-score matching.

The regular use of ivermectin led to a 68% reduction in COVID-19 mortality (25 [0.8%] versus 79 [2.6%] among ivermectin non-users; RR, 0.32; 95% CI, 0.20-0.49; p < 0.0001).

Kerr L et al., 2022-01-15: The Itajaí, Brazil citywide programme report: among 159,561 residents analysed, regular ivermectin users had 44% lower infection, 56% lower hospitalisation and 68% lower COVID-19 mortality than non-users after propensity-score matching. Prospective observational study with propensity-score matching; 223,128 residents considered, 159,561 analysed (113,845 regular users, 45,716 non-users), Itajaí, Santa Catarina, Brazil, July-December 2020. Dose: ivermectin 0.2 mg/kg/day for two consecutive days every 15 days, offered optionally to the whole population; participants who fell ill were advised not to use ivermectin as early outpatient treatment. Comparator: non-users, propensity-matched on age, sex and comorbidities. Authors declare no competing interests; two authors (Kory, Chamie-Quintero) are FLCCC-affiliated, which the paper does not flag as a conflict. No randomisation and no blinding , the design is the basis of the published criticism that such observational analyses cannot separate the drug from healthy-user effects. Study type: controlled study.